Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Jaeger

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647Steven B Gendreau, Richard Ventura, Paul Keast, et al.
Molecular Cancer Therapeutics|March 18, 2014
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathwayPeiwen Yu, A Douglas Laird, Xiangnan Du, et al.
Molecular Cancer Therapeutics|February 1, 2015
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor ModelsPaul Foster, Kyoko Yamaguchi, Pin P Hsu, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647Steven B Gendreau, Richard Ventura, Paul Keast, et al.
Molecular Cancer Therapeutics|March 18, 2014
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathwayPeiwen Yu, A Douglas Laird, Xiangnan Du, et al.
Molecular Cancer Therapeutics|February 1, 2015
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor ModelsPaul Foster, Kyoko Yamaguchi, Pin P Hsu, et al.
Pageof 7